Tags

Type your tag names separated by a space and hit enter

[Prevalence of anti-hepatitis A in patients with chronic liver disease].
Gastroenterol Hepatol. 1998 Aug-Sep; 21(7):324-6.GH

Abstract

The recent availability of an effective vaccine for preventing hepatitis A has led to the performance of a prevalence study of antibodies versus the hepatitis A virus (HAV) in our patients with chronic liver disease by hepatitis B and C, as a step prior to vaccination. The sera of 425 patients with a mean age of 40 years was studied, with the global antibodies versus HAV being determined (Abbott). The prevalence was to 75.2% varying from 20% at 19 years to 93% in those over the age of 40. The prevalence was not related to sex, previous parenteral history, or drug addiction or infection by hepatitis B or C. Due to previous cost-benefit studies and the high prevalence found, the determination of anti-HAV in patients with chronic viral liver diseases prior to vaccination against HAV is recommended.

Authors+Show Affiliations

Diago M
Servicio de Digestivo, Hospital General Universitario, Valencia.
Luján M
No affiliation info available
García V
No affiliation info available
Cors R
No affiliation info available
Carbonell P
No affiliation info available
Tuset C
No affiliation info available
Gimeno J
No affiliation info available

MeSH

AdolescentAdultChildFemaleHepatitis AHepatitis AntibodiesHepatitis B, ChronicHepatitis C, ChronicHepatovirusHumansMaleSeroepidemiologic StudiesVaccinationViral Hepatitis Vaccines

Pub Type(s)

English Abstract
Journal Article

Language

spa

PubMed ID

9808894

Citation

Diago, M, et al. "[Prevalence of Anti-hepatitis a in Patients With Chronic Liver Disease]." Gastroenterologia Y Hepatologia, vol. 21, no. 7, 1998, pp. 324-6.
Diago M, Luján M, García V, et al. [Prevalence of anti-hepatitis A in patients with chronic liver disease]. Gastroenterol Hepatol. 1998;21(7):324-6.
Diago, M., Luján, M., García, V., Cors, R., Carbonell, P., Tuset, C., & Gimeno, J. (1998). [Prevalence of anti-hepatitis A in patients with chronic liver disease]. Gastroenterologia Y Hepatologia, 21(7), 324-6.
Diago M, et al. [Prevalence of Anti-hepatitis a in Patients With Chronic Liver Disease]. Gastroenterol Hepatol. 1998 Aug-Sep;21(7):324-6. PubMed PMID: 9808894.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Prevalence of anti-hepatitis A in patients with chronic liver disease]. AU - Diago,M, AU - Luján,M, AU - García,V, AU - Cors,R, AU - Carbonell,P, AU - Tuset,C, AU - Gimeno,J, PY - 1998/11/11/pubmed PY - 1998/11/11/medline PY - 1998/11/11/entrez SP - 324 EP - 6 JF - Gastroenterologia y hepatologia JO - Gastroenterol Hepatol VL - 21 IS - 7 N2 - The recent availability of an effective vaccine for preventing hepatitis A has led to the performance of a prevalence study of antibodies versus the hepatitis A virus (HAV) in our patients with chronic liver disease by hepatitis B and C, as a step prior to vaccination. The sera of 425 patients with a mean age of 40 years was studied, with the global antibodies versus HAV being determined (Abbott). The prevalence was to 75.2% varying from 20% at 19 years to 93% in those over the age of 40. The prevalence was not related to sex, previous parenteral history, or drug addiction or infection by hepatitis B or C. Due to previous cost-benefit studies and the high prevalence found, the determination of anti-HAV in patients with chronic viral liver diseases prior to vaccination against HAV is recommended. SN - 0210-5705 UR - https://www.unboundmedicine.com/medline/citation/9808894/[Prevalence_of_anti_hepatitis_A_in_patients_with_chronic_liver_disease]_ L2 - http://www.diseaseinfosearch.org/result/4280 DB - PRIME DP - Unbound Medicine ER -